loading page

Dupilumab for Chronic Eosinophilic Pneumonia
  • Christopher Fowler,
  • Wynton Hoover
Christopher Fowler
The University of Alabama at Birmingham

Corresponding Author:[email protected]

Author Profile
Wynton Hoover
Indiana University
Author Profile


Chronic Eosinophilic Pneumonia (CEP) is a rare idiopathic eosinophilic lung disease characterized by a triad of pulmonary symptoms, radiographic findings and peripheral and/or lung eosinophilia. CEP is usually treated with oral corticosteroids however, treatment durations commonly exceed 12 months, relapses occur in ½ of patients and adverse effects of steroid use are common. We report a case of an 11-year-old female with corticosteroid refractory CEP who experienced clinical remission after initiation of dupilumab, a monoclonal antibody therapy approved for eosinophilic or steroid dependent asthma that inhibits IL-4 and IL-13. This case demonstrates the potential role of biologic agents in CEP.
Dec 2020Published in Pediatric Pulmonology volume 55 issue 12 on pages 3229-3230. 10.1002/ppul.25096